Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Seminars in Hematology|July 5, 2025
Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implicationsKasper J Croese, Jacqueline Cloos, Jesse M Tettero
Cancers|June 2, 2021
AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AMLDiana Hanekamp, Jesse M Tettero, Gert J Ossenkoppele, et al.
The Cochrane Database of Systematic Reviews|March 12, 2019
Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancerEsmee Cm Kooijmans, Arend Bökenkamp, Nic S Tjahjadi, et al.
Haematologica|May 28, 2026
Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysisJesse M Tettero, Mei-Jie Zhang, Wentong Liu, et al.
Plos Computational Biology|February 2, 2024
Covering Hierarchical Dirichlet Mixture Models on binary data to enhance genomic stratifications in onco-hematologyDaniele Dall'Olio, Eric Sträng, Amin T Turki, et al.
Cytometry. Part B, Clinical Cytometry|September 28, 2023
Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometryJesse M Tettero, Naveen Dakappagari, Maaike E Heidinga, et al.
Leukemia|January 25, 2024
Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemiaJesse M Tettero, Maaike E Heidinga, Tim R Mocking, et al.
Hemasphere|December 29, 2021
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working PartyJesse M Tettero, Sylvie Freeman, Veit Buecklein, et al.
Frontiers in Oncology|October 27, 2022
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysisJesse M Tettero, Waleed K W Al-Badri, Lok Lam Ngai, et al.
Hemasphere|June 8, 2026
Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studiesCoen R Veenstra, Lok Lam Ngai, Patrycja Gradowska, et al.
Pageof 2